Table 1. Clinicopathologic Features of 174 Patients Treated with Neoadjuvant Chemotherapy.
| Characteristics | N (%) |
|---|---|
| Age at diagnosis (years) | 43.8 (± 8.1) |
| Mean tumour size (mm) | 62.0 (± 27.3) |
| Clinical T stage at diagnosis | |
| cT1 | 5 (2.9) |
| cT2 | 64 (36.8) |
| cT3 | 84 (48.3) |
| cT4 | 21 (12.1) |
| Clinical N stage at diagnosis | |
| cN0 | 18 (10.3) |
| cN1 | 49 (28.2) |
| cN2 | 57 (32.8) |
| cN3 | 50 (28.7) |
| Pathologic T stage | |
| ypTis | 11 (6.3) |
| ypT0 | 43 (24.7) |
| ypT1 | 45 (25.9) |
| ypT2 | 38 (21.8) |
| ypT3 | 36 (20.7) |
| ypT4 | 1 (0.6) |
| Pathologic N stage | |
| ypN0 | 73 (42.0) |
| ypN1 | 49 (28.2) |
| ypN2 | 23 (13.2) |
| ypN3 | 29 (16.7) |
| Estrogen receptor | |
| Positive | 93 (53.4) |
| Negative | 81 (46.6) |
| Progesterone receptor | |
| Positive | 72 (41.4) |
| Negative | 102 (58.6) |
| HER2 amplification | |
| Positive | 59 (33.9) |
| Negative | 115 (66.1) |
| Ki-67 | |
| ≤ 14% | 66 (48.9) |
| > 14% | 69 (51.1) |
| Type of surgery | |
| Breast conserving surgery | 103 (59.2) |
| Modified radical mastectomy | 71 (40.8) |
| Regimens of neoadjuvant chemotherapy | |
| AC | 67 (38.5) |
| AT | 15 (8.6) |
| AC-T | 46 (26.4) |
| HER2/neu monoclonal antibody based chemotherapy | 46 (26.4) |
| Histology | |
| Invasive ductal carcinoma | 165 (94.8) |
| Invasive lobular carcinoma | 4 (2.3) |
| Others | 5 (2.9) |
| EIC | |
| No | 98 (75.4) |
| Yes | 32 (24.6) |
| Histologic grade | |
| 1 | 23 (17.7) |
| 2 | 75 (57.7) |
| 3 | 32 (24.6) |
| Lymphovascular invasion | |
| No | 72 (49.7) |
| Yes | 73 (50.3) |
Chemotherapy regimens: A, adriamycin; C, cyclophosphamide; T, docetaxel. EIC = extensive intraductal component, HER2 = human epidermal growth factor receptor 2